These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34174338)

  • 1. Acute thrombogenicity of fluoropolymer coated stents versus competitive drug-eluting stents under single antiplatelet therapy.
    Sato Y; Jinnouchi H; Kolodgie FD; Cheng Q; Janifer C; Kutyna M; Sakamoto A; Cornelissen A; Mori M; Kawakami R; Kawai K; Fernandez R; Ghosh SKB; Romero ME; Perkins LEL; Virmani R; Finn AV
    Int J Cardiol; 2021 Sep; 338():42-49. PubMed ID: 34174338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of acute thrombogenicity and albumin adsorption in three different durable polymer coronary drug-eluting stents.
    Jinnouchi H; Kutyna M; Torii S; Cheng Q; Sakamoto A; Guo L; Cornelissen A; Perkins LEL; Hossainy SF; Pacetti SD; Kolodgie FD; Virmani R; Finn AV
    EuroIntervention; 2021 Jun; 17(3):248-256. PubMed ID: 32149708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Thrombogenicity of a Durable Polymer Everolimus-Eluting Stent Relative to Contemporary Drug-Eluting Stents With Biodegradable Polymer Coatings Assessed Ex Vivo in a Swine Shunt Model.
    Otsuka F; Cheng Q; Yahagi K; Acampado E; Sheehy A; Yazdani SK; Sakakura K; Euller K; Perkins LEL; Kolodgie FD; Virmani R; Joner M
    JACC Cardiovasc Interv; 2015 Aug; 8(9):1248-1260. PubMed ID: 26292590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute thrombogenicity of fluoropolymer-coated versus biodegradable and polymer-free stents.
    Torii S; Cheng Q; Mori H; Lipinski MJ; Acampado E; Perkins LEL; Hossainy SF; Pacetti SD; Kolodgie FD; Virmani R; Finn AV
    EuroIntervention; 2019 Mar; 14(16):1685-1693. PubMed ID: 29619983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Endothelial Barrier Functional Recovery After Implantation of a Novel Biodegradable-Polymer Sirolimus-Eluting Stent in Comparison to Durable- and Biodegradable-Polymer Everolimus-Eluting Stents.
    Sakamoto A; Torii S; Jinnouchi H; Guo L; Cornelissen A; Kuntz S; Cheng Q; Fernandez R; Paek KH; Harris K; Srivastava MC; Kolodgie FD; Virmani R; Finn AV
    Cardiovasc Revasc Med; 2021 Mar; 24():1-10. PubMed ID: 32928693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year clinical outcomes of zotarolimus- and everolimus-eluting durable-polymer-coated stents versus biolimus-eluting biodegradable-polymer-coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary intervention: data from the KAMIR.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Heart Vessels; 2019 Feb; 34(2):237-250. PubMed ID: 30167772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients.
    D'Ascenzo F; Iannaccone M; Saint-Hilary G; Bertaina M; Schulz-Schüpke S; Wahn Lee C; Chieffo A; Helft G; Gili S; Barbero U; Biondi Zoccai G; Moretti C; Ugo F; D'Amico M; Garbo R; Stone G; Rettegno S; Omedè P; Conrotto F; Templin C; Colombo A; Park SJ; Kastrati A; Hildick-Smith D; Gasparini M; Gaita F
    Eur Heart J; 2017 Nov; 38(42):3160-3172. PubMed ID: 29020300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
    Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboresistance and endothelial healing in polymer-coated versus polymer-free drug-eluting stents: Implications for short-term dual anti-platelet therapy.
    Jinnouchi H; Sato Y; Cheng Q; Janifer C; Kutyna M; Cornelissen A; Wijeratne R; Sakamoto A; Guo L; Kolodgie FD; Tunev S; Virmani R; Finn AV
    Int J Cardiol; 2021 Mar; 327():52-57. PubMed ID: 33242506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Strut Coverage in Patients Receiving Drug-Eluting Stents and its Implications for Dual Antiplatelet Therapy: A Randomized Trial.
    Lee SY; Kim JS; Yoon HJ; Hur SH; Lee SG; Kim JW; Hong YJ; Kim KS; Choi SY; Shin DH; Nam CM; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    JACC Cardiovasc Imaging; 2018 Dec; 11(12):1810-1819. PubMed ID: 29454763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised comparison of coronary stents according to short or prolonged durations of dual antiplatelet therapy in patients with acute coronary syndromes: a pre-specified analysis of the SMART-DATE trial.
    Jang WJ; Lee JB; Song YB; Choi KH; Choi SH; Chun WJ; Oh JH; Park IH; Doh JH; Jeong JO; Park JS; Gwon HC; Hahn JY
    EuroIntervention; 2021 Aug; 17(5):e411-e417. PubMed ID: 33136005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombogenicity and early vascular healing response in metallic biodegradable polymer-based and fully bioabsorbable drug-eluting stents.
    Koppara T; Cheng Q; Yahagi K; Mori H; Sanchez OD; Feygin J; Wittchow E; Kolodgie FD; Virmani R; Joner M
    Circ Cardiovasc Interv; 2015 Jun; 8(6):e002427. PubMed ID: 26022535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboresistance and functional healing in the COBRA PzF stent versus competitor DES: implications for dual antiplatelet therapy.
    Jinnouchi H; Mori H; Cheng Q; Kutyna M; Torii S; Sakamoto A; Guo L; Acampado E; Gupta A; Kolodgie FD; Virmani R; Finn AV
    EuroIntervention; 2019 Jul; 15(4):e342-e353. PubMed ID: 30375338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Very early neointimal coverage of new biodegradable polymer drug-eluting stent compared with durable polymer everolimus-eluting stent evaluated by optical frequency domain imaging.
    Kobayashi N; Ito Y; Yamawaki M; Araki M; Sakai T; Sakamoto Y; Mori S; Tsutsumi M; Nauchi M; Honda Y; Tokuda T; Makino K; Shirai S; Hirano K
    Int J Cardiovasc Imaging; 2018 Apr; 34(4):515-522. PubMed ID: 29159531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen), a randomized, controlled, noninferiority trial.
    Park KW; Kang SH; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Hur SH; Ryu JK; Lee BR; Park YW; Chae IH; Kim HS;
    J Am Coll Cardiol; 2014 Jul; 63(25 Pt A):2805-16. PubMed ID: 24814486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy profile of bioresorbable-polylactide-polymer-biolimus-A9-eluting stents versus durable-polymer-everolimus- and zotarolimus-eluting stents in patients with acute coronary syndrome.
    Jaguszewski M; Dörig M; Frangieh AH; Ghadri JR; Cammann VL; Diekmann J; Napp LC; D'Ascenzo F; Imori Y; Obeid S; Maier W; Lüscher TF; Templin C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):E173-E182. PubMed ID: 27377554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Durable-Polymer- and Biodegradable-Polymer-Based Newer-Generation Drug-Eluting Stents in Patients with Acute Myocardial Infarction and Prediabetes After Successful Percutaneous Coronary Intervention.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Kim S; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Int Heart J; 2020 Jul; 61(4):673-684. PubMed ID: 32684595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.
    Kang SH; Chae IH; Park JJ; Lee HS; Kang DY; Hwang SS; Youn TJ; Kim HS
    JACC Cardiovasc Interv; 2016 Jun; 9(12):1203-1212. PubMed ID: 27262860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
    Zbinden R; Piccolo R; Heg D; Roffi M; Kurz DJ; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Franzone A; Eberli F; Jüni P; Windecker S; Pilgrim T
    J Am Heart Assoc; 2016 Mar; 5(3):e003255. PubMed ID: 26979080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.